Businessman composing a successful financial chart with arrow going up, he is using green paper cuts, eco business and financial success concept

Editas Medicine, Inc. [NASDAQ: EDIT] shares went higher by 1.74% from its previous closing of $30.39, now trading at the price of $30.92, also adding 0.53 points. Is EDIT stock a buy or should you stay away?

The stock had a rather active trading session with the latest closing, by far recording 1.14 million contracts. Compared to the average trading volume of EDIT shares, the company saw a far better performance. Moreover, the stock has a 50.24M float and a +2.11% run over in the last seven days. EDIT share price has been hovering between $31.78 and $17.80 lately, and is definitely worthy of attention.

Editas Medicine, Inc. [NASDAQ:EDIT]: Analyst Rating and Earnings

Its stock price has been found in the range of 17.80 to 31.78. This is compared to its latest closing price of $30.39.

Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on Thu 27 Feb (In 81 Days).

Fundamental Analysis of Editas Medicine, Inc. [EDIT]

Now let’s turn to look at profitability: with a current Operating Margin for Editas Medicine, Inc. [EDIT] sitting at -356.10.

This company’s Return on Total Capital is -43.94, and its Return on Invested Capital has reached -42.30%. Its Return on Equity is -49.50, and its Return on Assets is -27.71. These metrics suggest that this Editas Medicine, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Editas Medicine, Inc. [EDIT] has generated a Total Debt to Total Equity ratio of 13.73. Similarly,

its Total Debt to Total Capital is 12.07, while its Total Debt to Total Assets stands at 7.71.

What about valuation? This company’s Enterprise Value to EBITDA is -11.31. The Enterprise Value to Sales for this firm is now 86.99, and its Total Debt to Enterprise Value stands at 0.04. Editas Medicine, Inc. [EDIT] has a Price to Book Ratio of 4.70.

Shifting the focus to workforce efficiency, Editas Medicine, Inc. [EDIT] earns $240,128 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 90.09 and its Total Asset Turnover is 0.08. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 10.44 and its Current Ratio is 10.44. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Editas Medicine, Inc. [EDIT] has 50.42M shares outstanding, amounting to a total market cap of $1.56B. Its stock price has been found in the range of 17.80 to 31.78. At its current price, it has moved down by -2.71% from its 52-week high, and it has moved up 73.71% from its 52-week low.

This stock’s Beta value is currently 2.62, which indicates that it is 4.65% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 79.78. This RSI suggests that Editas Medicine, Inc. is currently Overbought.

Conclusion: Is Editas Medicine, Inc. [EDIT] a Reliable Buy?

Shares of Editas Medicine, Inc. [EDIT], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.